In Vivo Flow Cytometric Evaluation of Circulating Metastatic Pancreatic Tumor Cells After High-Intensity Focused Ultrasound Therapy
Overview
Affiliations
We examined our hypothesis that high-intensity focused ultrasound (HIFU) treatment of pancreatic ductal adenocarcinoma (PDAC) in nude mice models may lead to an increased occurrence of hematogenous metastasis. The human PDAC cell line BxPC-3 transfected with mCherry was implanted into nude mice to establish orthotopic and subcutaneous xenograft (OX and SX) tumor models. Mice were exposed to HIFU when tumor sizes reached approximately 200-300 mm . The OX and SX tumor models were monitored continuously for tumor growth characteristics and hematogenous metastasis using in vivo flow cytometric (IVFC) detection of circulating tumor cells (CTCs) from the pancreas. We chose an appropriate mouse model to further examine whether or not HIFU increases the potential risk of hematogenous metastasis, using IVFC detection. Our results showed that the CTC number was greater in the OX model than in the SX model. The CTC number in the OX model increased gradually over time, whereas the CTC number in the SX model remained low. Therefore, the OX model was better for studying tumor metastasis by IVFC detection. We found significantly decreased CTC numbers and tumor volume after HIFU ablation. Our results showed the applicability of the PDAC OX tumor model for studying the occurrence of tumor metastasis due to the generation of CTCs. HIFU ablation substantially restricted PDAC hematogenous metastasis and provided effective tumor control locally. © 2020 The Authors. Cytometry Part A published by Wiley Periodicals Inc., on behalf of International Society for Advancement of Cytometry.
Thim E, Kitelinger L, Rivera-Escalera F, Mathew A, Elliott M, Bullock T Theranostics. 2024; 14(4):1647-1661.
PMID: 38389838 PMC: 10879863. DOI: 10.7150/thno.92089.
Coppola A, Grasso D, Fontana F, Piacentino F, Minici R, Lagana D J Clin Med. 2023; 12(24).
PMID: 38137745 PMC: 10743777. DOI: 10.3390/jcm12247677.
Thim E, Kitelinger L, Rivera-Escalera F, Mathew A, Elliott M, Bullock T bioRxiv. 2023; .
PMID: 37732205 PMC: 10508728. DOI: 10.1101/2023.09.02.552844.
Latest Advances in the Use of Therapeutic Focused Ultrasound in the Treatment of Pancreatic Cancer.
Mouratidis P, Ter Haar G Cancers (Basel). 2022; 14(3).
PMID: 35158903 PMC: 8833696. DOI: 10.3390/cancers14030638.
Editorial: Modulation of Human Immune Parameters by Anticancer Therapies.
Sack U, Tarnok A, Preijers F, Kohl U, Na I Front Immunol. 2020; 11:621556.
PMID: 33343586 PMC: 7738630. DOI: 10.3389/fimmu.2020.621556.